Home › Funds › Royalty Pharma Sub-Manager, LLC › CYTK
Royalty Pharma Sub-Manager, LLC position in CYTK
CYTOKINETICS INC · Health Care
Royalty Pharma Sub-Manager, LLC reported holding 980,392 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$64.6M, representing 32.92% of its reported portfolio and ranking #1 among its reported holdings. Royalty Pharma Sub-Manager, LLC has disclosed CYTK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Royalty Pharma Sub-Manager, LLC's CYTK position evolved
Royalty Pharma Sub-Manager, LLC first disclosed a stake in CYTK in Q4 2025 at 980,392 shares (US$62.3M). The position peaked in Q2 2026 at 980,392 shares, worth US$83.5M. Across 4 filings, Royalty Pharma Sub-Manager, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 980,392 shares valued at US$64.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 980.39K | $62.29M | New |
| Q1 2026 | 980.39K | $64.62M | Hold |
| Q2 2026 | 980.39K | $83.52M | Hold |
| Q3 2026 | 980.39K | $64.62M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 42 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M sh · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M sh · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M sh · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M sh · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M sh · $102.34M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- GW&K Investment Management, LLC 1.02M sh · $67.08M · Q3 2026
- Melqart Asset Management (UK) Ltd 767.52K sh · $65.39M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
- Deep Track Capital, LP 700.00K sh · $59.63M · Q2 2026
- Affinity Asset Advisors, LLC 750.00K sh · $49.43M · Q3 2026
More on Royalty Pharma Sub-Manager, LLC
FAQ
How long has Royalty Pharma Sub-Manager, LLC held CYTK?
Royalty Pharma Sub-Manager, LLC has disclosed CYTK holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Royalty Pharma Sub-Manager, LLC's current position in CYTK?
As of Q3 2026, Royalty Pharma Sub-Manager, LLC holds 980.39K shares of CYTK (CYTOKINETICS INC), valued at $64.62M, representing 32.92% of its reported portfolio and ranking #1.
Has Royalty Pharma Sub-Manager, LLC been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Royalty Pharma Sub-Manager, LLC held unchanged its position in CYTK. The position peaked in Q2 2026 at 980.39K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.